Merck Draws (Vioxx online) Split Decision

Merck Draws (Vioxx online) Split Decision

Merck Draws Split Decision
Street.Com - Jurors in Atlantic City, N.J. issued a split verdict Wednesday, saying that Merck's ( MRK :NYSE - news - research - Cramer's Take ) arthritis drug Vioxx was a "substantial factor" in the heart attack of one man but that it didn't cause the heart
Source: www.thestreet.com

Maximum 4 weeks to see arthritis specialist, guidelines urge
Globe and Mail - Canadians suspected of having rheumatoid arthritis and other inflammatory joint conditions should be seen by a specialist within four weeks, and, if necessary, begin treatment immediately. That is just one of a dozen sweeping recommendations
Source: www.theglobeandmail.com

Merck Must Pay $4.5M In Vioxx Case
CBS News - (AP) The verdict capped a monthlong trial in which lawyers for Cona and McDarby laid out now-familiar accusations that Merck rushed the drug to market in a losing battle against competitor Celebrex and actively ignored evidence it was causing
Source: www.cbsnews.com

Ex-FDA official ends testimony in Vioxx trial
MSN MoneyCentral - ATLANTIC CITY, New Jersey (Reuters) - An former official from the U.S. Food and Drug Administration on Friday said Merck & Co. Inc. properly submitted all information on its Vioxx drug to the regulators, ending testimony in the punitive phase of the
Source: moneycentral.msn.com

Jury finds company liable in Vioxx trial
Los Angeles Daily News - ATLANTIC CITY, N.J. - A jury found Merck & Co. liable on Wednesday for one of two former Vioxx users' heart attacks in a split verdict that awarded $4.5 million in damages to one of the plaintiffs. The state jury found the company failed to
Source: www.dailynews.com

Summary of developments in Vioxx trial
BusinessWeek - APR. 7 6:37 P.M. ET THE CASE: Jurors are trying to determine whether Vioxx manufacturer Merck & Co. should pay John McDarby $4.5 million in damages punitive damages for failing to warn of the drug's risks. FRIDAY'S DEVELOPMENTS: The judge denied a
Source: www.businessweek.com

Former CEO denies Merck withheld information about Vioxx from FDA
Philadelphia Inquirer - ATLANTIC CITY, N.J. - In his first appearance in a Vioxx trial, the former chief executive of Merck & Co. insisted Thursday that the company was up front about the safety risks of its troubled arthritis drug during his tenure - despite a jury verdict
Source: www.philly.com